Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. Show more

Location: 2450 Holcombe Blvd, Houston, TX, 77021, United States | Website: https://markertherapeutics.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

11.21M

52 Wk Range

$0.81 - $5.95

Previous Close

$0.87

Open

$0.85

Volume

596,523

Day Range

$0.84 - $0.90

Enterprise Value

749.6K

Cash

10.46M

Avg Qtr Burn

-2.721M

Insider Ownership

7.08%

Institutional Own.

26.32%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MT-601 (Neldaleucel) Details Non-Hodgkin Lymphoma (NHL)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MT-401-OTS Details Acute myeloid leukemia	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MT-601 (Neldaleucel) + chemotherapy Details Pancreatic cancer	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MT-401 Details Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.